Masahiko Nagata, Jin Kozakai, Aya Yoshida, Kana Kameyama, Hiromi Oboso, Hisanori Muto, Shoji Ogino, Toshihiro Tsukui
{"title":"Immunotherapy using pullulan-conjugated Der f 2 allergen in canine atopic dermatitis: An anti-inflammatory agent-sparing approach.","authors":"Masahiko Nagata, Jin Kozakai, Aya Yoshida, Kana Kameyama, Hiromi Oboso, Hisanori Muto, Shoji Ogino, Toshihiro Tsukui","doi":"10.1111/vde.13315","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD).</p><p><strong>Objective: </strong>To assess the anti-inflammatory agent-sparing effect over 1 year of immunotherapy using pullulan-conjugated recombinant Der f 2 (rDf2-P).</p><p><strong>Animals: </strong>Twenty-one privately owned dogs with cAD.</p><p><strong>Materials and methods: </strong>Dogs with mild clinical signs after ≥4 weeks of anti-inflammatory drug treatment received rDf2-P immunotherapy for 1 year. A monthly medication score (MS) was calculated, and clinical signs were assessed using Canine Atopic Dermatitis Extent and Severity Index (CADESI)-04, cAD Eczema Area and Severity for Shiba Inu and pruritus scores. Serum thymus and activation-regulated chemokine (TARC)/C-C Motif Chemokine Ligand-17 (CCL17) concentrations were assessed at the initial and final doses during the 6-week induction phase and every 3 months for 1 year thereafter in 16 cases.</p><p><strong>Results: </strong>The mean MS decreased significantly by 43.0% (p = 0.022), 60.9% (p = 0.003), 70.0% (p = 0.0004), 58.7% (p = 0.0004) and 49.3% (p = 0.029) at 2.5, 4.5, 7.5, 10.5 and 13.5 months, respectively. Drug-sparing effects, assessed with MS and adjusted by clinical scores were rated as excellent for 12 (57.1%) and 11 (52.4%) dogs, good for 3 (14.3%) and 1 (4.8%) dogs, fair for 0 and 3 (14.3%) dogs, and poor for 6 (28.6%) and 5 (23.8%) dogs at 4.5 and 13.5 months, respectively. The serum TARC/CCL17 concentrations were significantly lower in the samples with lower CADESI-04 scores (<17) than in those with higher CADESI-04 scores (>17) (p = 0.0002).</p><p><strong>Conclusions and clinical relevance: </strong>Der f 2-P immunotherapy can lead to a rapid reduction in anti-inflammatory drug use and serve as an effective proactive therapy for cAD.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary dermatology","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/vde.13315","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD).
Objective: To assess the anti-inflammatory agent-sparing effect over 1 year of immunotherapy using pullulan-conjugated recombinant Der f 2 (rDf2-P).
Animals: Twenty-one privately owned dogs with cAD.
Materials and methods: Dogs with mild clinical signs after ≥4 weeks of anti-inflammatory drug treatment received rDf2-P immunotherapy for 1 year. A monthly medication score (MS) was calculated, and clinical signs were assessed using Canine Atopic Dermatitis Extent and Severity Index (CADESI)-04, cAD Eczema Area and Severity for Shiba Inu and pruritus scores. Serum thymus and activation-regulated chemokine (TARC)/C-C Motif Chemokine Ligand-17 (CCL17) concentrations were assessed at the initial and final doses during the 6-week induction phase and every 3 months for 1 year thereafter in 16 cases.
Results: The mean MS decreased significantly by 43.0% (p = 0.022), 60.9% (p = 0.003), 70.0% (p = 0.0004), 58.7% (p = 0.0004) and 49.3% (p = 0.029) at 2.5, 4.5, 7.5, 10.5 and 13.5 months, respectively. Drug-sparing effects, assessed with MS and adjusted by clinical scores were rated as excellent for 12 (57.1%) and 11 (52.4%) dogs, good for 3 (14.3%) and 1 (4.8%) dogs, fair for 0 and 3 (14.3%) dogs, and poor for 6 (28.6%) and 5 (23.8%) dogs at 4.5 and 13.5 months, respectively. The serum TARC/CCL17 concentrations were significantly lower in the samples with lower CADESI-04 scores (<17) than in those with higher CADESI-04 scores (>17) (p = 0.0002).
Conclusions and clinical relevance: Der f 2-P immunotherapy can lead to a rapid reduction in anti-inflammatory drug use and serve as an effective proactive therapy for cAD.
期刊介绍:
Veterinary Dermatology is a bi-monthly, peer-reviewed, international journal which publishes papers on all aspects of the skin of mammals, birds, reptiles, amphibians and fish. Scientific research papers, clinical case reports and reviews covering the following aspects of dermatology will be considered for publication:
-Skin structure (anatomy, histology, ultrastructure)
-Skin function (physiology, biochemistry, pharmacology, immunology, genetics)
-Skin microbiology and parasitology
-Dermatopathology
-Pathogenesis, diagnosis and treatment of skin diseases
-New disease entities